Esperion Therapeutics has reached a settlement agreement with Hetero USA and its affiliates, resolving a patent litigation case concerning the generic version of NEXLETOL® (bempedoic acid). According to the agreement, Hetero USA will not market a generic version of NEXLETOL in the United States before April 19, 2040, unless specific conditions outlined in the agreement occur. Meanwhile, patent litigation with other defendants is ongoing, and it remains uncertain if a generic version of NEXLETOL or NEXLIZET will be available in the U.S. before the specified date.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461343-en) on June 02, 2025, and is solely responsible for the information contained therein.